Nuveen Asset Management LLC Buys 347,993 Shares of Replimune Group, Inc. (NASDAQ:REPL)

Nuveen Asset Management LLC grew its holdings in Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 108.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 667,634 shares of the company's stock after purchasing an additional 347,993 shares during the quarter. Nuveen Asset Management LLC owned about 0.98% of Replimune Group worth $8,085,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Boxer Capital Management LLC bought a new position in shares of Replimune Group in the fourth quarter valued at about $21,754,000. Price T Rowe Associates Inc. MD lifted its holdings in Replimune Group by 11.0% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 10,962,883 shares of the company's stock worth $132,761,000 after buying an additional 1,083,633 shares in the last quarter. Marshall Wace LLP acquired a new stake in shares of Replimune Group in the 4th quarter valued at $10,853,000. Wellington Management Group LLP increased its stake in shares of Replimune Group by 352.5% in the 4th quarter. Wellington Management Group LLP now owns 1,096,744 shares of the company's stock valued at $13,282,000 after buying an additional 854,346 shares during the period. Finally, Artisan Partners Limited Partnership acquired a new stake in Replimune Group in the fourth quarter worth about $7,399,000. Institutional investors and hedge funds own 92.53% of the company's stock.

Replimune Group Stock Performance

Shares of Replimune Group stock traded down $0.44 on Friday, hitting $8.93. The stock had a trading volume of 2,181,119 shares, compared to its average volume of 938,252. The business's 50 day moving average is $8.39 and its two-hundred day moving average is $11.09. The stock has a market cap of $688.39 million, a price-to-earnings ratio of -2.91 and a beta of 0.68. Replimune Group, Inc. has a twelve month low of $4.93 and a twelve month high of $17.00. The company has a quick ratio of 11.43, a current ratio of 11.43 and a debt-to-equity ratio of 0.14.

Replimune Group (NASDAQ:REPL - Get Free Report) last posted its quarterly earnings data on Thursday, May 22nd. The company reported ($0.82) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.07). During the same period last year, the company earned ($0.25) EPS. Analysts forecast that Replimune Group, Inc. will post -2.97 EPS for the current year.

Insiders Place Their Bets

In other Replimune Group news, insider Christopher Sarchi sold 3,749 shares of the business's stock in a transaction that occurred on Tuesday, May 20th. The stock was sold at an average price of $8.05, for a total value of $30,179.45. Following the transaction, the insider now directly owns 128,296 shares of the company's stock, valued at approximately $1,032,782.80. The trade was a 2.84% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CAO Andrew Schwendenman sold 3,287 shares of the business's stock in a transaction on Tuesday, May 20th. The shares were sold at an average price of $8.05, for a total transaction of $26,460.35. Following the transaction, the chief accounting officer now owns 68,284 shares in the company, valued at $549,686.20. The trade was a 4.59% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 74,907 shares of company stock valued at $603,655. 8.80% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several analysts have commented on REPL shares. JPMorgan Chase & Co. upped their target price on shares of Replimune Group from $16.00 to $18.00 and gave the company an "overweight" rating in a research report on Wednesday, February 26th. HC Wainwright boosted their price target on shares of Replimune Group from $21.00 to $22.00 and gave the stock a "buy" rating in a research report on Thursday, February 13th. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Replimune Group presently has a consensus rating of "Buy" and an average target price of $19.43.

Replimune Group Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.